Reported 12 months ago
Benefiting from a vibrant market investment atmosphere and boosted by themes like weight-loss drugs and medical materials, the biotech and healthcare sector stocks have steadily risen in performance, with the top ten biotech funds showing accumulated returns of over 10% this year. The demand in the biotech and healthcare industry remains strong, and with various thematic supports in medical sub-industries, there is still hope to attract fund allocations. Opportunities in the weight-loss drug market are promising, and advancements in medical devices like robot-assisted surgeries and structural heart diseases indicate significant market growth potential, attracting investments in mid and small-cap biotech stocks. Mergers and acquisitions (M&A) continue to brew in the biotech industry, particularly with large pharmaceutical companies expected to have substantial funds for acquisitions, benefiting overall industry development. Innovation in biotech technologies is seen as a long-term core competitive advantage in the industry, with a focus on oncology, neurology, and rare diseases. Despite capital market volatility, M&A activities in the biotech sector have maintained fervor, signaling emerging investment value.
Source: YAHOO